Top

Published in:

Open Access 01-12-2023 | Colorectal Cancer | Research

Tumor necrosis factor-α-inducible protein 8-like protein 3 (TIPE3): a novel prognostic factor in colorectal cancer

Authors: Yue Xu, Yong Zhu, Hengbo Xia, Yanan Wang, Lin Li, Hong Wan, Shuping Zhang, Aman Xu, Liecheng Wang, Jiao Gong, Pingping Zhang

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

To explore the correlation of tumor necrosis factor-α-induced protein 8-like protein 3 (TIPE3) expressions in colorectal cancer (CRC) with tumor-immune infiltration and patient prognosis.

Methods

Formalin-fixed paraffin-embedded tumor samples from CRC patients (n = 110) were used in this study. Immunohistochemistry staining of TIPE3 and three prognostic immune biomarkers (CD8, CD20, and CD66b) was conducted in the tumor tissues and adjacent normal tissues. A Cox regression analysis of univariate and multivariate variables was performed to assess the correlation between TIPE3 and patient prognosis.

Result

We found that TIPE3 was mainly expressed in the cytoplasm, with a small amount in the nucleus. The expression of TIPE3 in tumor tissues is significantly higher than in adjacent normal tissues, and it is significantly correlated with the survival rate of patients in tumor tissues (p = 0.0038) and adjacent normal tissues (p<0.0001). Patients with a high TIPE3 expression had a lower survival rate, while patients with a low TIPE3 expression had a higher survival rate. Univariate regression analysis showed that the TIPE3 expression in tumor tissues (p = 0.007), the TIPE3 expression in adjacent normal tissues (p<0.001), the number of CD8+ T cells in tumor tissues (p = 0.020), the number of CD20+ B cells in tumor tissues (p = 0.023), the number of CD20+ B cells in adjacent normal tissues (p = 0.023), the number of CD66b+ neutrophils in tumor tissues (p = 0.005), the number of CD66b+ neutrophils in adjacent normal tissues (p<0.001), lymphatic metastasis (p = 0.010), TNM stage (p = 0.013), and tumor grade (p = 0.027) were significantly correlated with overall survival (OS). These prognostic factors were then subjected to multivariate regression analysis, and the results showed that the expression of TIPE3, the number of CD8+ T cells, and the number of CD66b+ neutrophils were prognostic factors affecting the OS rate of CRC patients.

Conclusion

We found that the TIPE3 protein is upregulated in CRC cancer tissues and is correlated with survival rate.

Available only for authorised users

Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30. https://doi.org/10.1002/cncr.33587.CrossRef

World Health Organization (WHO). Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019. Geneva: World Health Organization; 2020. http://who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death.

Yang Y, Han Z, Li X, et al. Epidemiology and risk factors of colorectal cancer in China[J]. Chin J Cancer Res. 2020;32(6):729–41.CrossRef

Padmavathi G, Banik K, Monisha J, Bordoloi D, Shabnam B, Arfuso F, Sethi G, Fan L, Kunnumakkara AB. Novel tumor necrosis factor-alpha induced protein eight (TNFAIP8/TIPE) family: Functions and downstream targets involved in cancer progression. Cancer Lett. 2018;432:260–71. https://doi.org/10.1016/j.canlet.2018.06.017.CrossRef

Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 2008;133(3):415–26. https://doi.org/10.1016/j.cell.2008.03.026.CrossRef

Bordoloi D, Banik K, Shabnam B, Padmavathi G, Monisha J, Arfuso F, Dharmarajan A, Mao X, Lim LHK, Wang L, Fan L, Hui KM, Kumar AP, Sethi G, Kunnumakkara AB. TIPE Family of Proteins and Its Implications in Different Chronic Diseases. Int J Mol Sci. 2018;19(10):2974. https://doi.org/10.3390/ijms19102974. (PMID: 30274259; PMCID: PMC6213092).CrossRef

Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, Yuan J. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell. 2008;135(7):1311–23. https://doi.org/10.1016/j.cell.2008.10.044.CrossRef

Cui J, Zhang G, Hao C, et al. The expression of TIPE1 in murine tissues and human cell lines [J]. Mol Immunol. 2011;48(12-13):1548–55.

Lian K, Ma C, Hao C, et al. TIPE3 protein promotes breast cancer metastasis through activating AKT and NF-kappaB signaling pathways. Oncotarget. 2017;8(30):48889–904.CrossRef

10.

Wang G, Guo C, Zhao H, et al. TIPE3 differentially modulates proliferation and migration of human non-small-cell lung cancer cells via distinct subcellular location[J]. BMC Cancer. 2018;18(1):260.CrossRef

11.

Yuan F, Liu B, Xu Y, Li Y, Sun Q, Xu P, Geng R, Den G, Yang J, Zhang S, Gao L, Liao J, Liu J, Yang X, Tan Y, Chen Q. TIPE3 is a regulator of cell apoptosis in glioblastoma. Cancer Lett. 2019;1(446):1–14. https://doi.org/10.1016/j.canlet.2018.12.019. (Epub 2019 Jan 11 PMID: 30639532).CrossRef

12.

Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10:205. https://doi.org/10.1186/1479-5876-10-205.CrossRef

13.

Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28(6):690–714. https://doi.org/10.1016/j.ccell.2015.10.012.CrossRef

14.

Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, Kim WH. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008;99(10):1704–11. https://doi.org/10.1038/sj.bjc.6604738.CrossRef

15.

Wu Y, Zhao Q, Peng C, Sun L, Li XF, Kuang DM. Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop. J Pathol. 2011;225(3):438–47. https://doi.org/10.1002/path.2947.CrossRef

16.

Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for Colorectal Cancer Screening. Gastroenterology. 2020;158(2):418–32. https://doi.org/10.1053/j.gastro.2019.06.043.CrossRef

17.

Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64. https://doi.org/10.3322/caac.21601.CrossRef

18.

Wancata LM, Banerjee M, Muenz DG, Haymart MR, Wong SL. Conditional survival in advanced colorectal cancer and surgery. J Surg Res. 2016;201(1):196–201. https://doi.org/10.1016/j.jss.2015.10.021.CrossRef

19.

Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017;109(9):djx015. https://doi.org/10.1093/jnci/djx015.CrossRef

20.

Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139–47. https://doi.org/10.1002/cncr.32163.CrossRef

21.

Zhong M, Chen Z, Yan Y, Bahet A, Cai X, Chen H, Ran H, Qu K, Han Z, Zhuang G, Zhang S, Wang Y. Expression of TIPE family members in human colorectal cancer. Oncol Lett. 2021;21(2):118. https://doi.org/10.3892/ol.2020.12379. (Epub 2020 Dec 15. PMID: 33376549; PMCID: PMC7751461).CrossRef

22.

Padmavathi G, Banik K, Monisha J, Bordoloi D, Shabnam B, Arfuso F, Sethi G, Fan L, Kunnumakkara AB. Novel tumor necrosis factor-α induced protein eight (TNFAIP8/TIPE) family: Functions and downstream targets involved in cancer progression. Cancer Lett. 2018;28(432):260–71. https://doi.org/10.1016/j.canlet.2018.06.017. (Epub 2018 Jun 18 PMID: 29920292).CrossRef

23.

Fayngerts SA, Wu J, Oxley CL, et al. TIPE3 is the transfer protein of lipid second messengers that promote cancer[J]. Cancer Cell. 2014;26(4):465–78.CrossRef

24.

Finck A, Gill SI, June CH. Cancer immunotherapy comes of age and looks for maturity. Nat Commun. 2020;11(1):3325. https://doi.org/10.1038/s41467-020-17140-5.CrossRef

25.

Jiang X, Xu J, Liu M, Xing H, Wang Z, Huang L, Mellor AL, Wang W, Wu S. Adoptive CD8(+) T cell therapy against cancer: Challenges and opportunities. Cancer Lett. 2019;462:23–32. https://doi.org/10.1016/j.canlet.2019.07.017.CrossRef

26.

Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–62. https://doi.org/10.1146/annurev.immunol.21.120601.141122.CrossRef

27.

Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–32. https://doi.org/10.1038/nri2343.CrossRef

28.

Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5:15179. https://doi.org/10.1038/srep15179.CrossRef

Title: Tumor necrosis factor-α-inducible protein 8-like protein 3 (TIPE3): a novel prognostic factor in colorectal cancer
Authors: Yue Xu
Yong Zhu
Hengbo Xia
Yanan Wang
Lin Li
Hong Wan
Shuping Zhang
Aman Xu
Liecheng Wang
Jiao Gong
Pingping Zhang
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-10590-2

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

ESCO2 promotes hypopharyngeal carcinoma progression in a STAT1-dependent manner

Correction: Overexpression of CENPL mRNA potentially regulated by miR-340-3p predicts the prognosis of pancreatic cancer patients

Carboxylated superparamagnetic Fe3O4 nanoparticles modified with 3-amino propanol and their application in magnetic resonance tumor imaging

A deep-learning approach for segmentation of liver tumors in magnetic resonance imaging using UNet++

Etiological analysis of infection after CRS + HIPEC in patients with PMP